Cleared Traditional

K810188 - AUTO SUTURE GAS POWERED DISP. LDS STAPL (FDA 510(k) Clearance)

Class I Ear, Nose, Throat device.

K810188 · United States Surgical, A Division of Tyco Healthc · Ear, Nose, Throat device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Mar 1981
Decision
57d
Days
Class 1
Risk

K810188 is an FDA 510(k) clearance for the AUTO SUTURE GAS POWERED DISP. LDS STAPL. Classified as Saw, Nasal (product code KBC), Class I - General Controls.

Submitted by United States Surgical, A Division of Tyco Healthc (Walker, US). The FDA issued a Cleared decision on March 20, 1981 after a review of 57 days - a notably fast clearance cycle.

This device falls under the Ear, Nose, Throat FDA review panel, regulated under 21 CFR 874.4420 - the FDA ear, nose and throat device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all United States Surgical, A Division of Tyco Healthc devices

Submission Details

510(k) Number K810188 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 22, 1981
Decision Date March 20, 1981
Days to Decision 57 days
Submission Type Traditional
Review Panel Ear, Nose, Throat (EN)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
32d faster than avg
Panel avg: 89d · This submission: 57d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code KBC Saw, Nasal
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 874.4420
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.